Trial Outcomes & Findings for Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma (NCT NCT00523848)

NCT ID: NCT00523848

Last Updated: 2017-02-23

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

46 participants

Primary outcome timeframe

Every 3 months

Results posted on

2017-02-23

Participant Flow

Participant milestones

Participant milestones
Measure
Arm 1 - VDT: VELCADE, Doxil and Low-dose Thalidomide
Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
Overall Study
STARTED
46
Overall Study
Treated With Study Therapy
44
Overall Study
COMPLETED
22
Overall Study
NOT COMPLETED
24

Reasons for withdrawal

Reasons for withdrawal
Measure
Arm 1 - VDT: VELCADE, Doxil and Low-dose Thalidomide
Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
Overall Study
Adverse Event
11
Overall Study
Withdrawal by Subject
2
Overall Study
NOT TREATED (Became ineligible)
2
Overall Study
Disease Progression
5
Overall Study
Other, unspecified
4

Baseline Characteristics

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=40 Participants
Age, Continuous
60.13 years
STANDARD_DEVIATION 9.34 • n=5 Participants
Gender
Female
14 Participants
n=5 Participants
Gender
Male
26 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Every 3 months

Population: Evaluable patients

Outcome measures

Outcome measures
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=40 Participants
Overall Response Rate (Complete and Partial)
77.50 percentage of participants
Interval 61.55 to 89.16

SECONDARY outcome

Timeframe: Every 3 months

Population: Evaluable patients.

Outcome measures

Outcome measures
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=40 Participants
Complete Response Rate
22.50 percentage of participants
Interval 10.84 to 38.45

SECONDARY outcome

Timeframe: Every 3 monthsntil the date of first documented progression or date of death from any cause, whichever came first

Outcome measures

Outcome measures
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=40 Participants
Time to Disease Progression
27.8 months
Interval 17.7 to 32.1

Adverse Events

VDT: VELCADE, Doxil and Low-dose Thalidomide

Serious events: 16 serious events
Other events: 44 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=44 participants at risk
Blood and lymphatic system disorders
Febrile neutropenia - Grade 3
2.3%
1/44 • Number of events 1
Cardiac disorders
Bradycardia - Grade 2
2.3%
1/44 • Number of events 1
Cardiac disorders
Cardiac failure congestive - Grade 3
4.5%
2/44 • Number of events 2
Cardiac disorders
Sinus bradycardia - Grade 2
2.3%
1/44 • Number of events 1
Endocrine disorders
Hypothyroidism - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Asthenia - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Chills - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Oedema peripheral - Grade 3
2.3%
1/44 • Number of events 1
General disorders
Pain - Grade 2
4.5%
2/44 • Number of events 2
General disorders
Pyrexia - Grade 1
4.5%
2/44 • Number of events 2
General disorders
Pyrexia - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Pyrexia - Grade 3
2.3%
1/44 • Number of events 1
Infections and infestations
Pneumococcal bacteraemia - Grade 3
2.3%
1/44 • Number of events 1
Infections and infestations
Pneumonia - Grade 3
13.6%
6/44 • Number of events 6
Infections and infestations
Sepsis - Grade 3
2.3%
1/44 • Number of events 1
Investigations
Lipids abnormal - Grade 1
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Cachexia - Grade 2
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Dehydration - Grade 2
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Failure to thrive - Grade 1
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hypoalbuminaemia - Grade 1
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Metabolic acidosis - Grade 2
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Back pain - Grade 3
2.3%
1/44 • Number of events 1
Nervous system disorders
Headache - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Polyneuropathy - Grade 3
2.3%
1/44 • Number of events 1
Nervous system disorders
Spinal cord compression - Grade 3
2.3%
1/44 • Number of events 1
Psychiatric disorders
Suicide attempt - Grade 4
2.3%
1/44 • Number of events 1
Renal and urinary disorders
Renal failure acute - Grade 2
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Dyspnoea - Grade 2
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Dyspnoea - Grade 3
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Hypoxia - Grade 3
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease - Grade 3
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Pleural effusion - Grade 3
6.8%
3/44 • Number of events 3
Respiratory, thoracic and mediastinal disorders
Pleural effusion - Grade 4
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism - Grade 3
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Respiratory failure - Grade 4
2.3%
1/44 • Number of events 1
Vascular disorders
Hypertension - Grade 2
2.3%
1/44 • Number of events 1

Other adverse events

Other adverse events
Measure
VDT: VELCADE, Doxil and Low-dose Thalidomide
n=44 participants at risk
Blood and lymphatic system disorders
Anaemia - Grade 1
18.2%
8/44 • Number of events 9
Blood and lymphatic system disorders
Anaemia - Grade 2
20.5%
9/44 • Number of events 9
Blood and lymphatic system disorders
Anaemia - Grade 3
4.5%
2/44 • Number of events 2
Blood and lymphatic system disorders
Leukopenia - Grade 1
43.2%
19/44 • Number of events 22
Blood and lymphatic system disorders
Leukopenia - Grade 2
25.0%
11/44 • Number of events 15
Blood and lymphatic system disorders
Leukopenia - Grade 3
15.9%
7/44 • Number of events 7
Blood and lymphatic system disorders
Lymphopenia - Grade 1
29.5%
13/44 • Number of events 14
Blood and lymphatic system disorders
Lymphopenia - Grade 2
31.8%
14/44 • Number of events 15
Blood and lymphatic system disorders
Lymphopenia - Grade 3
25.0%
11/44 • Number of events 11
Blood and lymphatic system disorders
Neutropenia - Grade 1
13.6%
6/44 • Number of events 7
Blood and lymphatic system disorders
Neutropenia - Grade 2
29.5%
13/44 • Number of events 16
Blood and lymphatic system disorders
Neutropenia - Grade 3
18.2%
8/44 • Number of events 9
Blood and lymphatic system disorders
Neutropenia - Grade 4
2.3%
1/44 • Number of events 1
Blood and lymphatic system disorders
Thrombocytopenia - Grade 1
15.9%
7/44 • Number of events 11
Blood and lymphatic system disorders
Thrombocytopenia - Grade 2
9.1%
4/44 • Number of events 5
Blood and lymphatic system disorders
Thrombocytopenia - Grade 3
4.5%
2/44 • Number of events 2
Cardiac disorders
Bradycardia - Grade 1
6.8%
3/44 • Number of events 3
Cardiac disorders
Cyanosis - Grade 1
2.3%
1/44 • Number of events 1
Cardiac disorders
Tachycardia - Grade 1
2.3%
1/44 • Number of events 1
Ear and labyrinth disorders
Deafness - Grade 1
2.3%
1/44 • Number of events 1
Ear and labyrinth disorders
Deafness - Grade 2
2.3%
1/44 • Number of events 1
Ear and labyrinth disorders
Ear pain - Grade 1
2.3%
1/44 • Number of events 1
Eye disorders
Blepharitis - Grade 2
2.3%
1/44 • Number of events 1
Eye disorders
Diplopia - Grade 1
2.3%
1/44 • Number of events 1
Eye disorders
Dry eye - Grade 2
2.3%
1/44 • Number of events 1
Eye disorders
Eye swelling - Grade 1
2.3%
1/44 • Number of events 1
Eye disorders
Eyelid ptosis - Grade 2
2.3%
1/44 • Number of events 1
Eye disorders
Lacrimation increased - Grade 1
2.3%
1/44 • Number of events 1
Eye disorders
Meibomianitis - Grade 2
2.3%
1/44 • Number of events 1
Eye disorders
Vision blurred - Grade 1
9.1%
4/44 • Number of events 4
Eye disorders
Vision blurred - Grade 2
2.3%
1/44 • Number of events 1
Eye disorders
Visual disturbance - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Abdominal discomfort - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Abdominal distension - Grade 1
9.1%
4/44 • Number of events 4
Gastrointestinal disorders
Abdominal pain - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Abdominal pain upper - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Constipation - Grade 1
61.4%
27/44 • Number of events 27
Gastrointestinal disorders
Diarrhoea - Grade 1
22.7%
10/44 • Number of events 12
Gastrointestinal disorders
Dry mouth - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Dyspepsia - Grade 1
6.8%
3/44 • Number of events 3
Gastrointestinal disorders
Dysphagia - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Flatulence - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Haemorrhoids - Grade 1
2.3%
1/44 • Number of events 1
Gastrointestinal disorders
Nausea - Grade 1
22.7%
10/44 • Number of events 11
Gastrointestinal disorders
Stomatitis - Grade 1
4.5%
2/44 • Number of events 2
Gastrointestinal disorders
Vomiting - Grade 1
13.6%
6/44 • Number of events 6
General disorders
Asthenia - Grade 1
18.2%
8/44 • Number of events 8
General disorders
Asthenia - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Axillary pain - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Chest discomfort - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Chest pain - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Chills - Grade 1
9.1%
4/44 • Number of events 4
General disorders
Fatigue - Grade 1
50.0%
22/44 • Number of events 24
General disorders
Fatigue - Grade 2
13.6%
6/44 • Number of events 7
General disorders
Fatigue - Grade 3
6.8%
3/44 • Number of events 3
General disorders
Feeling hot - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Gait disturbance - Grade 1
6.8%
3/44 • Number of events 3
General disorders
Gait disturbance - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Influenza like illness - Grade 1
6.8%
3/44 • Number of events 3
General disorders
Non-cardiac chest pain - Grade 1
4.5%
2/44 • Number of events 2
General disorders
Oedema - Grade 1
11.4%
5/44 • Number of events 5
General disorders
Oedema - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Oedema peripheral - Grade 1
31.8%
14/44 • Number of events 15
General disorders
Oedema peripheral - Grade 2
4.5%
2/44 • Number of events 2
General disorders
Pain - Grade 1
9.1%
4/44 • Number of events 4
General disorders
Pain - Grade 2
2.3%
1/44 • Number of events 1
General disorders
Pyrexia - Grade 1
18.2%
8/44 • Number of events 8
General disorders
Tenderness - Grade 1
2.3%
1/44 • Number of events 1
General disorders
Xerosis - Grade 1
2.3%
1/44 • Number of events 1
Hepatobiliary disorders
Hyperbilirubinaemia - Grade 1
2.3%
1/44 • Number of events 1
Hepatobiliary disorders
Hyperbilirubinaemia - Grade 2
2.3%
1/44 • Number of events 1
Immune system disorders
Drug hypersensitivity - Grade 1
2.3%
1/44 • Number of events 1
Immune system disorders
Hypersensitivity - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Bacterial infection - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Breast cellulitis - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Cystitis - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Eye infection - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Fungal infection - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Furuncle - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Hordeolum - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Infection - Grade 1
4.5%
2/44 • Number of events 2
Infections and infestations
Lobar pneumonia - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Localised infection - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Nasopharyngitis - Grade 1
6.8%
3/44 • Number of events 3
Infections and infestations
Oral candidiasis - Grade 1
4.5%
2/44 • Number of events 2
Infections and infestations
Oral candidiasis - Grade 2
2.3%
1/44 • Number of events 2
Infections and infestations
Pneumonia - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Pneumonia - Grade 2
9.1%
4/44 • Number of events 5
Infections and infestations
Pneumonia - Grade 3
2.3%
1/44 • Number of events 1
Infections and infestations
Rash pustular - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Sinusitis - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Tinea cruris - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Tinea infection - Grade 1
2.3%
1/44 • Number of events 1
Infections and infestations
Tinea pedis - Grade 2
2.3%
1/44 • Number of events 1
Infections and infestations
Upper respiratory tract infection - Grade 1
2.3%
1/44 • Number of events 1
Injury, poisoning and procedural complications
Open wound - Grade 1
2.3%
1/44 • Number of events 1
Investigations
Alanine aminotransferase increased - Grade 1
11.4%
5/44 • Number of events 5
Investigations
Alanine aminotransferase increased - Grade 2
2.3%
1/44 • Number of events 1
Investigations
Aspartate aminotransferase increased - Grade 1
31.8%
14/44 • Number of events 14
Investigations
Aspartate aminotransferase increased - Grade 2
4.5%
2/44 • Number of events 2
Investigations
Blood alkaline phosphatase - Grade 1
4.5%
2/44 • Number of events 2
Investigations
Blood alkaline phosphatase increased - Grade 1
20.5%
9/44 • Number of events 11
Investigations
Blood creatine increased - Grade 1
6.8%
3/44 • Number of events 3
Investigations
Blood creatine increased - Grade 2
2.3%
1/44 • Number of events 1
Investigations
Heart rate decreased - Grade 1
2.3%
1/44 • Number of events 1
Investigations
Heart rate decreased - Grade 2
2.3%
1/44 • Number of events 1
Investigations
International normalised ratio increased - Grade 1
2.3%
1/44 • Number of events 1
Investigations
Weight decreased - Grade 1
2.3%
1/44 • Number of events 1
Investigations
Weight decreased - Grade 2
2.3%
1/44 • Number of events 1
Investigations
Weight decreased - Grade 3
2.3%
1/44 • Number of events 1
Investigations
Weight increased - Grade 1
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Anorexia - Grade 1
25.0%
11/44 • Number of events 11
Metabolism and nutrition disorders
Anorexia - Grade 2
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Anorexia - Grade 3
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Decreased appetite - Grade 1
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Hypercalcaemia - Grade 1
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Hypercalcaemia - Grade 2
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hyperglycaemia - Grade 1
29.5%
13/44 • Number of events 13
Metabolism and nutrition disorders
Hyperglycaemia - Grade 2
6.8%
3/44 • Number of events 3
Metabolism and nutrition disorders
Hyperglycaemia - Grade 3
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Hyperkalaemia - Grade 1
20.5%
9/44 • Number of events 14
Metabolism and nutrition disorders
Hyperkalaemia - Grade 2
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Hyperkalaemia - Grade 3
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hypernatraemia - Grade 1
18.2%
8/44 • Number of events 11
Metabolism and nutrition disorders
Hypernatraemia - Grade 2
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hyperuricaemia - Grade 4
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hypoalbuminaemia - Grade 1
9.1%
4/44 • Number of events 5
Metabolism and nutrition disorders
Hypoalbuminaemia - Grade 2
6.8%
3/44 • Number of events 3
Metabolism and nutrition disorders
Hypocalcaemia - Grade 1
25.0%
11/44 • Number of events 11
Metabolism and nutrition disorders
Hypocalcaemia - Grade 2
4.5%
2/44 • Number of events 2
Metabolism and nutrition disorders
Hypoglycaemia - Grade 1
18.2%
8/44 • Number of events 9
Metabolism and nutrition disorders
Hypoglycaemia - Grade 2
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Hypokalaemia - Grade 1
13.6%
6/44 • Number of events 9
Metabolism and nutrition disorders
Hyponatraemia - Grade 1
20.5%
9/44 • Number of events 10
Metabolism and nutrition disorders
Hyponatraemia - Grade 3
2.3%
1/44 • Number of events 1
Metabolism and nutrition disorders
Oral intake reduced - Grade 1
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Arthralgia - Grade 1
6.8%
3/44 • Number of events 4
Musculoskeletal and connective tissue disorders
Back pain - Grade 1
13.6%
6/44 • Number of events 6
Musculoskeletal and connective tissue disorders
Back pain - Grade 2
6.8%
3/44 • Number of events 3
Musculoskeletal and connective tissue disorders
Back pain - Grade 3
4.5%
2/44 • Number of events 2
Musculoskeletal and connective tissue disorders
Bone pain - Grade 1
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Bursitis - Grade 1
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Flank pain - Grade 1
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Muscle spasms - Grade 1
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Muscular weakness - Grade 1
6.8%
3/44 • Number of events 3
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain - Grade 1
4.5%
2/44 • Number of events 2
Musculoskeletal and connective tissue disorders
Musculoskeletal pain - Grade 1
6.8%
3/44 • Number of events 3
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness - Grade 1
4.5%
2/44 • Number of events 2
Musculoskeletal and connective tissue disorders
Myalgia - Grade 1
4.5%
2/44 • Number of events 2
Musculoskeletal and connective tissue disorders
Myalgia - Grade 2
2.3%
1/44 • Number of events 1
Musculoskeletal and connective tissue disorders
Pain in extremity - Grade 1
6.8%
3/44 • Number of events 3
Musculoskeletal and connective tissue disorders
Pain in extremity - Grade 2
4.5%
2/44 • Number of events 2
Musculoskeletal and connective tissue disorders
Pain in jaw - Grade 1
4.5%
2/44 • Number of events 2
Nervous system disorders
Amnesia - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Balance disorder - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Burning sensation - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Cluster headache - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Disturbance in attention - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Dizziness - Grade 1
38.6%
17/44 • Number of events 22
Nervous system disorders
Dizziness - Grade 2
2.3%
1/44 • Number of events 1
Nervous system disorders
Dysgeusia - Grade 1
6.8%
3/44 • Number of events 3
Nervous system disorders
Dysgeusia - Grade 2
2.3%
1/44 • Number of events 1
Nervous system disorders
Headache - Grade 1
4.5%
2/44 • Number of events 3
Nervous system disorders
Hypoaesthesia - Grade 1
4.5%
2/44 • Number of events 3
Nervous system disorders
Hypoaesthesia - Grade 2
2.3%
1/44 • Number of events 1
Nervous system disorders
Neuropathy - Grade 1
6.8%
3/44 • Number of events 4
Nervous system disorders
Neuropathy - Grade 3
2.3%
1/44 • Number of events 1
Nervous system disorders
Neuropathy peripheral - Grade 1
25.0%
11/44 • Number of events 11
Nervous system disorders
Neuropathy peripheral - Grade 2
6.8%
3/44 • Number of events 3
Nervous system disorders
Neuropathy peripheral - Grade 3
2.3%
1/44 • Number of events 1
Nervous system disorders
Paraesthesia - Grade 1
9.1%
4/44 • Number of events 4
Nervous system disorders
Parosmia - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Peripheral motor neuropathy - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Peripheral sensory neuropathy - Grade 1
2.3%
1/44 • Number of events 1
Nervous system disorders
Peripheral sensory neuropathy - Grade 2
2.3%
1/44 • Number of events 1
Nervous system disorders
Tremor - Grade 1
11.4%
5/44 • Number of events 5
Psychiatric disorders
Anxiety - Grade 1
2.3%
1/44 • Number of events 2
Psychiatric disorders
Confusional state - Grade 2
2.3%
1/44 • Number of events 1
Psychiatric disorders
Confusional state - Grade 4
2.3%
1/44 • Number of events 1
Psychiatric disorders
Illusion - Grade 1
2.3%
1/44 • Number of events 1
Psychiatric disorders
Insomnia - Grade 1
2.3%
1/44 • Number of events 1
Psychiatric disorders
Nervousness - Grade 1
2.3%
1/44 • Number of events 1
Psychiatric disorders
Panic attack - Grade 1
2.3%
1/44 • Number of events 1
Psychiatric disorders
Sleep disorder - Grade 1
2.3%
1/44 • Number of events 1
Renal and urinary disorders
Dysuria - Grade 1
2.3%
1/44 • Number of events 1
Renal and urinary disorders
Pollakiuria - Grade 1
2.3%
1/44 • Number of events 1
Renal and urinary disorders
Polyuria - Grade 1
2.3%
1/44 • Number of events 1
Renal and urinary disorders
Renal tubular acidosis - Grade 2
2.3%
1/44 • Number of events 1
Reproductive system and breast disorders
Pelvic pain - Grade 1
4.5%
2/44 • Number of events 2
Respiratory, thoracic and mediastinal disorders
Cough - Grade 1
22.7%
10/44 • Number of events 10
Respiratory, thoracic and mediastinal disorders
Dysphonia - Grade 1
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Dyspnoea - Grade 1
25.0%
11/44 • Number of events 11
Respiratory, thoracic and mediastinal disorders
Dyspnoea - Grade 2
4.5%
2/44 • Number of events 2
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional - Grade 1
11.4%
5/44 • Number of events 5
Respiratory, thoracic and mediastinal disorders
Hiccups - Grade 1
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Nasal congestion - Grade 1
4.5%
2/44 • Number of events 2
Respiratory, thoracic and mediastinal disorders
Oropharyngeal swelling - Grade 1
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Productive cough - Grade 1
2.3%
1/44 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea - Grade 1
4.5%
2/44 • Number of events 2
Respiratory, thoracic and mediastinal disorders
Wheezing - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Alopecia - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Blister - Grade 1
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Decubitus ulcer - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Drug eruption - Grade 1
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Drug eruption - Grade 3
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Dry skin - Grade 1
22.7%
10/44 • Number of events 10
Skin and subcutaneous tissue disorders
Dry skin - Grade 2
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Erythema - Grade 1
13.6%
6/44 • Number of events 6
Skin and subcutaneous tissue disorders
Erythema - Grade 2
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Hyperhidrosis - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome - Grade 1
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome - Grade 2
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome - Grade 3
6.8%
3/44 • Number of events 3
Skin and subcutaneous tissue disorders
Pigmentation disorder - Grade 1
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Pruritus - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Pruritus generalised - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash - Grade 1
22.7%
10/44 • Number of events 11
Skin and subcutaneous tissue disorders
Rash - Grade 2
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Rash erythematous - Grade 1
13.6%
6/44 • Number of events 6
Skin and subcutaneous tissue disorders
Rash erythematous - Grade 2
4.5%
2/44 • Number of events 2
Skin and subcutaneous tissue disorders
Rash erythematous - Grade 3
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash generalised - Grade 2
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash morbilliform - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash pruritic - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash pruritic - Grade 2
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Rash pruritic - Grade 3
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin atrophy - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin discolouration - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin disorder - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin disorder - Grade 2
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin exfoliation - Grade 1
6.8%
3/44 • Number of events 3
Skin and subcutaneous tissue disorders
Skin exfoliation - Grade 3
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin hyperpigmentation - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin irritation - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Skin lesion - Grade 1
2.3%
1/44 • Number of events 1
Skin and subcutaneous tissue disorders
Urticaria - Grade 1
2.3%
1/44 • Number of events 1
Vascular disorders
Deep vein thrombosis - Grade 3
2.3%
1/44 • Number of events 1
Vascular disorders
Hypertension - Grade 2
2.3%
1/44 • Number of events 1
Vascular disorders
Hypotension - Grade 1
2.3%
1/44 • Number of events 1
Vascular disorders
Hypotension - Grade 2
2.3%
1/44 • Number of events 1
Vascular disorders
Orthostatic hypotension - Grade 1
2.3%
1/44 • Number of events 1
Vascular disorders
Orthostatic hypotension - Grade 2
4.5%
2/44 • Number of events 2

Additional Information

Senior Administrator, Compliance - Clinical Research Services

Roswell Park Cancer Institute

Phone: 716-845-2300

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place